(Q36040685)

11 August 2017

1 reference

title

Mesalazine for diverticular disease of the colon--a new role for an old drug (English)

1 reference

11 August 2017

Antonio Tursi

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

69-74

1 reference

Diverticulitis: when and how to operate?

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Acute diverticulitis of the colon--current medical therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Management of uncomplicated acute diverticulitis: results of a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Medical therapy for ulcerative colitis 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Oxidants and free radicals in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Diverticular colitis: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

What is diverticular colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Segmental colitis: so what?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

Laparoscopic colectomy vs. open colectomy for sigmoid diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.69

21 January 2018

Identifiers

DOI

10.1517/14656566.6.1.69

1 reference

11 August 2017

1 reference